Business
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
Limited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, inclu
About this update from Microbot Medical Inc.
[{"type":"image","alt":"Microbot Medical Inc.","displaySize":"","headline":null,"caption":"Microbot Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":127,"url":"https://media.zenfs.com/en/globenewswire.com/9626a8786202041757b3030226d69d16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8sc4mubv858DmIYRrwJwfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9626a8786202041757b3030226d69d16","width":300,"height":127}},"lazy":false},{"type":"text","content":"Limited Market Release (LMR) of the LIBERTY® System is on Schedule","length":66,"tagName":"p"},{"type":"text","content":"Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2","length":126,"tagName":"p"},{"type":"text","content":"HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several pivotal achievements such as obtaining FDA 510(k) clearance for LIBERTY, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The Company initiated its limited market release, quickly achieving its first customer to adopt LIBERTY for patient care. The Company is positioning itself to leverage this momentum and commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually. This progress enables the Company to pursue and strive for the 2026 anticipated milestones listed below.","length":894,"tagName":"p"},{"type":"text","content":"Key 2025 Operational and Business Achievements","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received FDA clearance.","length":23,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched the Limited Market Release of LIBERTY, strategically introducing LIBERTY into select high procedure volume regions, leveraging early demand to accelerate adoption.","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Emory University Hospital, a nationally recognized academic medical center in Atlanta, became the first hospital t...